HONG KONG -- Biotech company Prenetics has lost more than one-third of its value since listing on the Nasdaq this week, as the Hong Kong startup's chief executive warned that a key virus-screening business was set for a steep fall.
Shares in the company, a COVID-19 test provider that helped soccer's Premier League resume matches, closed at $5.10 in New York on Thursday, down 40% from a high of $8.50 reached on its U.S. trading debut Wednesday.
